1. Updates in Triple-Negative Breast Cancer

2. Introduction to TNBC

3. Effects of BRCA Mutations and PARP Inhibitors on DNA Repair Mechanisms in TNBC

4. Effects of BRCA Mutations and PARP Inhibitors on DNA Repair Mechanisms in TNBC (cont)

5. OlympiAD Olaparib in Patients With mBC and Germline BRCA Mutations

6. OlympiAD Olaparib in Patients With mBC and Germline BRCA Mutations (cont)

7. EMBRACA Talazoparib in Patients With mBC and Germline BRCA Mutations

8. EMBRACA Talazoparib in Patients With mBC and Germline BRCA Mutations (cont)

9. PARP Inhibitor AEs

10. Drug-Drug Interactions With PARP Inhibitors

11. Guidelines for Testing in TNBC

12. IMpassion130 First Phase 3 Trial to Show Benefit With IO in TNBC

13. Overview of irAEs

14. Single-Agent Chemotherapy for PD-L1-Negative, BRCA-WT mTNBC[a]

15. Sacituzumab Govitecan Breakthrough Therapy in Heavily Treated Patients

16. Current Standard of Care for Locally Advanced TNBC

17. Platinum Agents in Neoadjuvant TNBC Therapy Yes or No?

18. Platinum Agents in Neoadjuvant TNBC Therapy Yes or No? (cont)

19. GeparOLA PARP Inhibition in TNBC Neoadjuvant Therapy

20. Emerging Anti-PD-1 Therapy in Neoadjuvant Treatment

21. KEYNOTE-522 Confirming Benefit of Pembrolizumab-Containing Neoadjuvant Therapy

22. KEYNOTE-522 Study Pathological Complete Response

23. Clinical Pearls for Practice

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)